Abstract
Different engineered heart muscle formats have been developed for applications in disease modeling, drug screening, and heart repair. The advantage of 3D engineered versus 2D monolayer and 3D aggregate cardiomyocyte cultures is a clearly advanced degree of maturation, which in many aspects resembles the postnatal rather than the embryonic or fetal heart, in the most advanced 3D culture formats. According to the desired in vitro (disease modeling or drug screening) and in vivo (heart repair) application, scale and geometry of tissue engineered heart muscle must be adapted. In this updated methods paper, we report a simple and scalable (up and down) collagen-based protocol for the construction of Engineered Human Myocardium (EHM) under defined, serum-free conditions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Zimmermann WH, Fink C, Kralisch D, Remmers U, Weil J, Eschenhagen T (2000) Three-dimensional engineered heart tissue from neonatal rat cardiac myocytes. Biotechnol Bioeng 68:106–114
Zimmermann WH, Schneiderbanger K, Schubert P, Didie M, Munzel F, Heubach JF, Kostin S, Neuhuber WL, Eschenhagen T (2002) Tissue engineering of a differentiated cardiac muscle construct. Circ Res 90:223–230
Kensah G, Roa Lara A, Dahlmann J, Zweigerdt R, Schwanke K, Hegermann J, Skvorc D, Gawol A, Azizian A, Wagner S et al (2013) Murine and human pluripotent stem cell-derived cardiac bodies form contractile myocardial tissue in vitro. Eur Heart J 34:1134–1146
Schaaf S, Shibamiya A, Mewe M, Eder A, Stohr A, Hirt MN, Rau T, Zimmermann WH, Conradi L, Eschenhagen T et al (2011) Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS One 6:e26397
Soong PL, Tiburcy M, Zimmermann WH (2012) Cardiac differentiation of human embryonic stem cells and their assembly into engineered heart muscle. Curr Protoc Cell Biol Chapter 23(Unit23):28
Tulloch NL, Muskheli V, Razumova MV, Korte FS, Regnier M, Hauch KD, Pabon L, Reinecke H, Murry CE (2011) Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ Res 109:47–59
Tiburcy M, Hudson JE, Balfanz P, Schlick S, Meyer T, Chang Liao ML, Levent E, Raad F, Zeidler S, Wingender E et al (2017) Defined engineered human myocardium with advanced maturation for applications in heart failure modeling and repair. Circulation 135:1832–1847
Hanses U, Kleinsorge M, Roos L, Yigit G, Li Y, Barbarics B, El-Battrawy I, Lan H, Tiburcy M, Hindmarsh R et al (2020) Intronic CRISPR repair in a preclinical model of noonan syndrome-associated cardiomyopathy. Circulation 142(11):1059–1076
Mills RJ, Parker BL, Quaife-Ryan GA, Voges HK, Needham EJ, Bornot A, Ding M, Andersson H, Polla M, Elliott DA et al (2019) Drug screening in human PSC-cardiac organoids identifies pro-proliferative compounds acting via the mevalonate pathway. Cell Stem Cell 24(895–907):e896
Riegler J, Tiburcy M, Ebert A, Tzatzalos E, Raaz U, Abilez OJ, Shen Q, Kooreman NG, Neofytou E, Chen VC et al (2015) Human engineered heart muscles engraft and survive long term in a rodent myocardial infarction model. Circ Res 117:720–730
Sasaki D, Matsuura K, Seta H, Haraguchi Y, Okano T, Shimizu T (2018) Contractile force measurement of human induced pluripotent stem cell-derived cardiac cell sheet-tissue. PLoS One 13:e0198026
Giacomelli E, Meraviglia V, Campostrini G, Cochrane A, Cao X, van Helden RWJ, Krotenberg Garcia A, Mircea M, Kostidis S, Davis RP et al (2020) Human-iPSC-derived cardiac stromal cells enhance maturation in 3D cardiac microtissues and reveal non-cardiomyocyte contributions to heart disease. Cell Stem Cell 26(862–879):e811
Pointon A, Pilling J, Dorval T, Wang Y, Archer C, Pollard C (2017) From the cover: high-throughput imaging of cardiac microtissues for the assessment of cardiac contraction during drug discovery. Toxicol Sci 155:444–457
Nunes SS, Miklas JW, Liu J, Aschar-Sobbi R, **ao Y, Zhang B, Jiang J, Masse S, Gagliardi M, Hsieh A et al (2013) Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nat Methods 10:781–787
Zhang D, Shadrin IY, Lam J, **an HQ, Snodgrass HR, Bursac N (2013) Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes. Biomaterials 34:5813–5820
Munarin F, Kaiser NJ, Kim TY, Choi BR, Coulombe KLK (2017) Laser-etched designs for molding hydrogel-based engineered tissues. Tissue Eng Part C Methods 23:311–321
Ronaldson-Bouchard K, Ma SP, Yeager K, Chen T, Song L, Sirabella D, Morikawa K, Teles D, Yazawa M, Vunjak-Novakovic G (2018) Advanced maturation of human cardiac tissue grown from pluripotent stem cells. Nature 556:239–243
Naito H, Melnychenko I, Didie M, Schneiderbanger K, Schubert P, Rosenkranz S, Eschenhagen T, Zimmermann WH (2006) Optimizing engineered heart tissue for therapeutic applications as surrogate heart muscle. Circulation 114:I72–I78
Kreutziger KL, Muskheli V, Johnson P, Braun K, Wight TN, Murry CE (2011) Develo** vasculature and stroma in engineered human myocardium. Tissue Eng A 17:1219–1228
Karbassi E, Fenix A, Marchiano S, Muraoka N, Nakamura K, Yang X, Murry CE (2020) Cardiomyocyte maturation: advances in knowledge and implications for regenerative medicine. Nat Rev Cardiol 17:341–359
Liaw NY, Zimmermann WH (2016) Mechanical stimulation in the engineering of heart muscle. Adv Drug Deliv Rev 96:156–160
Tiburcy M, Meyer T, Liaw NY, Zimmermann WH (2020) Generation of engineered human myocardium in a multi-well format. STAR Protoc 1:100032
Schlick SF, Spreckelsen F, Tiburcy M, Iyer LM, Meyer T, Zelarayan LC, Luther S, Parlitz U, Zimmermann WH, Rehfeldt F (2019) Agonistic and antagonistic roles of fibroblasts and cardiomyocytes on viscoelastic stiffening of engineered human myocardium. Prog Biophys Mol Biol 144:51–60
Zimmermann WH, Melnychenko I, Wasmeier G, Didie M, Naito H, Nixdorff U, Hess A, Budinsky L, Brune K, Michaelis B et al (2006) Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med 12:452–458
Burridge PW, Keller G, Gold JD, Wu JC (2012) Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell 10:16–28
Zimmermann WH (2021) Engineered heart muscle Models in phenotypic drug screens. Handb Exp Pharmacol 265:143–156. https://doi.org/10.1007/164_2020_385. PMID: 33136187
Cyganek L, Tiburcy M, Sekeres K, Gerstenberg K, Bohnenberger H, Lenz C, Henze S, Stauske M, Salinas G, Zimmermann WH, Hasenfuss G, Guan K (2018) Deep phenoty** of human induced pluripotent stem cell-derived atrial and ventricular cardiomyocytes. JCI Insight 3(12):e99941. https://doi.org/10.1172/jci.insight.99941. PMID: 29925689; PMCID: PMC6124434
Acknowledgments
M.T. is supported by the German Research Foundation (DFG TI 956/1-1, SFB 1002 C04). T.M. is supported by the DZHK (German Center for Cardiovascular Research; Shared Expertise Funding Scheme). P.L.S. is a member of DFG IRTG 1816. W.H.Z. is supported by the DZHK, the Leducq Foundation, the German Ministry for Science and Education (BMBF - IndiHeart), and the German Research Foundation (DFG SFB 1002 C04 and S01, IRTG 1816, MBExC - EXC 2067/1).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Ethics declarations
M.T., T.M., and W.H.Z. are listed as inventors of several granted and pending patent applications in the field of stem cell differentiation, tissue engineering, and tool development. The University Medical Center Göttingen has licensed related IP to myriamed GmbH and Repairon GmbH. W.H.Z. is founder and advisor of myriamed GmbH (active in drug screening) and Repairon GmbH (active in the clinical translation of tissue engineered heart repair). M.T. and T.M. are advisors of myriamed GmbH and Repairon GmbH.
Rights and permissions
Copyright information
© 2022 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Tiburcy, M., Meyer, T., Satin, PL., Zimmermann, WH. (2022). Defined Engineered Human Myocardium for Disease Modeling, Drug Screening, and Heart Repair. In: Coulombe, K.L., Black III, L.D. (eds) Cardiac Tissue Engineering. Methods in Molecular Biology, vol 2485. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2261-2_14
Download citation
DOI: https://doi.org/10.1007/978-1-0716-2261-2_14
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-2260-5
Online ISBN: 978-1-0716-2261-2
eBook Packages: Springer Protocols